February 21, 2018
Cytokinetics is currently conducting a Phase 2 clinical trial of CK-2127107 – now referred to by the generic name, reldesemtiv – which is designed to assess the investigational agent’s effect on multiple measures of muscle function in both ambulatory and non-ambulatory...
February 16, 2018
Cure SMA is extremely pleased to announce a generous $620,000 gift has been made to the organization. The donation was made anonymously in honor of William N. Kanehann. Billy had SMA and died in 2013 at the age of 23. We are grateful for this amazing donation in memory of his life.
This gift will be dedicated to supporting new...
February 14, 2018
Biogen has provided the following community statement on the final results from CHERISH, a Phase 3 study of SPINRAZA.
Dear Members of the SMA community,
This past December marked one year since the FDA approval of SPINRAZA® (nusinersen), the first and only treatment...